Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 24Head and Neck Neoplasms 21Lung Neoplasms 19Neoplasms 18Stomach Neoplasms 15Urinary Bladder Neoplasms 14Uterine Cervical Neoplasms 11Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Esophageal Neoplasms 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Biliary Tract Neoplasms 10Carcinoma, Transitional Cell 9Triple Negative Breast Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Oropharyngeal Neoplasms 7Mesothelioma, Malignant 7Melanoma 7Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Recurrence 5Nasopharyngeal Carcinoma 5Mesothelioma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Nasopharyngeal Neoplasms 4Mouth Neoplasms 4

Interventions

Injections 3toripalimab 2Carboplatin 2aflutinib 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1Chlorogenic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Lung Cancer × Cisplatin × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡